Literature DB >> 28791593

Key Pharmacokinetic Essentials of Fixed-Dosed Combination Products: Case Studies and Perspectives.

Ranjeet Prasad Dash1,2, Rana Rais1,2, Nuggehally R Srinivas3.   

Abstract

Fixed-dose combinations are gaining popularity because they provide convenience while enhancing patient compliance. Literature examples suggest that many fixed-dose combinations are being rationalized and investigated for their potential utility in therapy. This article provides an introspection into the pharmacokinetic essentials that need to be considered prior to implementing a fixed-dose combination strategy. While the drug-drug interaction potential is an important question for the two drugs in a fixed-dose combination, the occurrence of a drug-drug interaction in itself is not a negative outcome for the proposed fixed-dose combination. However, the magnitude of a drug-drug interaction may require a re-assessment of the doses of the two drugs in a fixed-dose combination. Several case studies are provided and discussed to provide a broad perspective on the topic along with a representative framework and strategy on the development of fixed-dose combinations using key pharmacokinetic parameters.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28791593     DOI: 10.1007/s40262-017-0589-2

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  36 in total

1.  Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects.

Authors:  Jayanti Mukherjee; Ayan Das; Uday S Chakrabarty; Bijay Sahoo; Pinaki Sengupta; Bappaditya Chatterjee; Bikash Roy; Tapan K Pal
Journal:  Arzneimittelforschung       Date:  2010

2.  2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stephane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  Blood Press       Date:  2013-12-20       Impact factor: 2.835

3.  Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers.

Authors:  A J Saah; G A Winchell; M L Nessly; M A Seniuk; R R Rhodes; P J Deutsch
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Authors:  D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 5.  A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes.

Authors:  Valerie Hutchins; Bin Zhang; Rachael L Fleurence; Girishanthy Krishnarajah; John Graham
Journal:  Curr Med Res Opin       Date:  2011-04-05       Impact factor: 2.580

6.  Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects.

Authors:  H Kusuhara; S Ito; Y Kumagai; M Jiang; T Shiroshita; Y Moriyama; K Inoue; H Yuasa; Y Sugiyama
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

7.  Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.

Authors:  Nils von Hentig; Axel Müller; Carsten Rottmann; Timo Wolf; Thomas Lutz; Stephan Klauke; Michael Kurowski; Bruno Oertel; Brenda Dauer; Sebastian Harder; Schlomo Staszewski
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

Review 8.  Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders.

Authors:  Ulrich Klotz
Journal:  Arzneimittelforschung       Date:  2009

9.  Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.

Authors:  Bijay Kumar Sahoo; Ayan Das; Sangita Agarwal; Uttam Bhaumik; Anirbandeep Bose; Debotri Ghosh; Bikash Roy; Tapan Kumar Pal
Journal:  Arzneimittelforschung       Date:  2009

Review 10.  How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.

Authors:  Andrew Hill; Jasper van der Lugt; Will Sawyer; Marta Boffito
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

View more
  2 in total

Review 1.  Emerging Multi-Drug Eutectics: Opportunities and Challenges.

Authors:  Jamshed Haneef; Shakir Ali; Renu Chadha
Journal:  AAPS PharmSciTech       Date:  2021-02-07       Impact factor: 3.246

2.  Pharmacokinetic Profiling and Simultaneous Determination of Thiopurine Immunosuppressants and Folic Acid by Chromatographic Methods.

Authors:  Edvin Brusač; Mario-Livio Jeličić; Daniela Amidžić Klarić; Biljana Nigović; Nikša Turk; Ilija Klarić; Ana Mornar
Journal:  Molecules       Date:  2019-09-24       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.